{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:08:11Z","timestamp":1790456891032,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fragile X syndrome (FXS) is caused by a full mutation of the <jats:italic>FMR1<\/jats:italic> gene (&gt;200 CGG repeats and subsequent methylation), such that there is little or no <jats:italic>FMR1<\/jats:italic> protein (FMRP) produced, leading to intellectual disability (ID). Individuals with the premutation allele (55\u2013200 CGG repeats, generally unmethylated) have elevated <jats:italic>FMR1<\/jats:italic> mRNA levels, a consequence of enhanced transcription, resulting in neuronal toxicity and a spectrum of premutation-associated disorders, including the neurodegenerative disorder fragile X-associated tremor\/ataxia syndrome (FXTAS). Here we described 14 patients who had both lowered FMRP and elevated <jats:italic>FMR1<\/jats:italic> mRNA levels, representing dual mechanisms of clinical involvement, which may combine features of both FXS and FXTAS. In addition, the majority of these cases show psychiatric symptoms, including bipolar disorder, and\/or psychotic features, which are rarely seen in those with just FXS.<\/jats:p>","DOI":"10.1038\/s41398-020-00863-w","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T14:03:06Z","timestamp":1592920986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Elevated FMR1-mRNA and lowered FMRP \u2013 A double-hit mechanism for psychiatric features in men with FMR1 premutations"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-7244","authenticated-orcid":false,"given":"Andrea","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri Indah","family":"Winarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4879-4896","authenticated-orcid":false,"given":"Ana Mar\u00eda","family":"Cabal-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bacalman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"863_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajmg.1320510404","volume":"51","author":"RJ Hagerman","year":"1994","unstructured":"Hagerman, R. J. et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am. J. Med. Genet. 51, 298\u2013308 (1994).","journal-title":"Am. J. Med. Genet."},{"key":"863_CR2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/(SICI)1096-8628(19990528)84:3<250::AID-AJMG17>3.0.CO;2-4","volume":"84","author":"F Tassone","year":"1999","unstructured":"Tassone, F. et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am. J. Med. Genet. 84, 250\u2013261 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"863_CR3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/(SICI)1096-8628(19990402)83:4<286::AID-AJMG10>3.0.CO;2-H","volume":"83","author":"WE Kaufmann","year":"1999","unstructured":"Kaufmann, W. E., Abrams, M. T., Chen, W. & Reiss, A. L. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am. J. Med. Genet. 83, 286\u2013295 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"863_CR4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mrdd.20006","volume":"10","author":"DZ Loesch","year":"2004","unstructured":"Loesch, D. Z., Huggins, R. M. & Hagerman, R. J. Phenotypic variation and FMRP levels in fragile X. Ment. Retard. Dev. Disabil. Res. Rev. 10, 31\u201341 (2004).","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"863_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/302720","volume":"66","author":"F Tassone","year":"2000","unstructured":"Tassone, F. et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet. 66, 6\u201315 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"863_CR6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00439-004-1086-x","volume":"114","author":"EG Allen","year":"2004","unstructured":"Allen, E. G., He, W., Yadav-Shah, M. & Sherman, S. L. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum. Genet. 114, 439\u2013447 (2004).","journal-title":"Hum. Genet."},{"key":"863_CR7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/374321","volume":"72","author":"S Jacquemont","year":"2003","unstructured":"Jacquemont, S. et al. Fragile X premutation tremor\/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am. J. Hum. Genet. 72, 869\u2013878 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"863_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.57.1.127","volume":"57","author":"RJ Hagerman","year":"2001","unstructured":"Hagerman, R. J. et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57, 127\u2013130 (2001).","journal-title":"Neurology"},{"key":"863_CR9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/humrep\/deh635","volume":"20","author":"AK Sullivan","year":"2005","unstructured":"Sullivan, A. K. et al. Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 20, 402\u2013412 (2005).","journal-title":"Hum. Reprod."},{"key":"863_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-013-1138-1","volume":"126","author":"P Hagerman","year":"2013","unstructured":"Hagerman, P. Fragile X-associated tremor\/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol. 126, 1\u201319 (2013).","journal-title":"Acta Neuropathol."},{"key":"863_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ajmg.b.20030","volume":"121B","author":"M Aziz","year":"2003","unstructured":"Aziz, M. et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121B, 119\u2013127 (2003).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"863_CR12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cortex.2006.11.002","volume":"44","author":"KM Cornish","year":"2008","unstructured":"Cornish, K. M. et al. Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex. 44, 628\u2013636 (2008).","journal-title":"Cortex."},{"key":"863_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bandc.2004.08.020","volume":"57","author":"K Cornish","year":"2005","unstructured":"Cornish, K. et al. The emerging fragile X premutation phenotype: evidence from the domain of social cognition. Brain Cogn. 57, 53\u201360 (2005).","journal-title":"Brain Cogn."},{"key":"863_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00439-011-1106-6","volume":"131","author":"W Chonchaiya","year":"2012","unstructured":"Chonchaiya, W. et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum. Genet. 131, 581\u2013589 (2012).","journal-title":"Hum. Genet."},{"key":"863_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004703-200604002-00012","volume":"27","author":"F Farzin","year":"2006","unstructured":"Farzin, F. et al. Autism spectrum disorders and attention-deficit\/hyperactivity disorder in boys with the fragile X premutation. J. Dev. Behav. Pediatr. 27, 137\u2013144 (2006).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"863_CR16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00004703-200412000-00002","volume":"25","author":"BL Goodlin-Jones","year":"2004","unstructured":"Goodlin-Jones, B. L., Tassone, F., Gane, L. W. & Hagerman, R. J. Autistic spectrum disorder and the fragile X premutation. J. Dev. Behav. Pediatr. 25, 392\u2013398 (2004).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"863_CR17","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/hmg\/ddu032","volume":"23","author":"AL Ludwig","year":"2014","unstructured":"Ludwig, A. L. et al. CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size. Hum. Mol. Genet. 23, 3228\u20133238 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"863_CR18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1017\/S1355838202020642","volume":"8","author":"B Primerano","year":"2002","unstructured":"Primerano, B. et al. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8, 1482\u20131488 (2002).","journal-title":"RNA"},{"key":"863_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004703-200602000-00012","volume":"27","author":"RJ Hagerman","year":"2006","unstructured":"Hagerman, R. J. Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. J. Dev. Behav. Pediatr. 27, 63\u201374 (2006).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"863_CR20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/14737159.2017.1377612","volume":"17","author":"P Jiraanont","year":"2017","unstructured":"Jiraanont, P. et al. Size and methylation mosaicism in males with Fragile X syndrome. Expert Rev. Mol. Diagn. 17, 1023\u20131032 (2017).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"863_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmedgenet-2013-102021","volume":"51","author":"DI Pretto","year":"2014","unstructured":"Pretto, D. I. et al. CGG allele size somatic mosaicism and methylation in FMR1 premutation alleles. J. Med. Genet. 51, 309\u2013318 (2014).","journal-title":"J. Med. Genet."},{"key":"863_CR22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/humu.22177","volume":"34","author":"RA Lokanga","year":"2013","unstructured":"Lokanga, R. A. et al. Somatic expansion in mouse and human carriers of fragile X premutation alleles. Hum. Mutat. 34, 157\u2013166 (2013).","journal-title":"Hum. Mutat."},{"key":"863_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2353\/jmoldx.2008.070073","volume":"10","author":"F Tassone","year":"2008","unstructured":"Tassone, F., Pan, R., Amiri, K., Taylor, A. K. & Hagerman, P. J. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J. Mol. Diagn. 10, 43\u201349 (2008).","journal-title":"J. Mol. Diagn."},{"key":"863_CR24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1373\/clinchem.2009.136101","volume":"56","author":"S Filipovic-Sadic","year":"2010","unstructured":"Filipovic-Sadic, S. et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin. Chem. 56, 399\u2013408 (2010).","journal-title":"Clin. Chem."},{"key":"863_CR25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2353\/jmoldx.2009.080118","volume":"11","author":"C Iwahashi","year":"2009","unstructured":"Iwahashi, C. et al. A quantitative ELISA assay for the fragile x mental retardation 1 protein. J. Mol. Diagn. 11, 281\u2013289 (2009).","journal-title":"J. Mol. Diagn."},{"key":"863_CR26","unstructured":"Reynolds, C. & Kamphaus, R. BASC-2 Behavior Assessment System for Children. (AGS Publishing, MN, 2004)."},{"key":"863_CR27","volume-title":"Anxiety Disorders Interview Schedule for DSM-IV: Lifetime version (ADIS-IV-L).","author":"P di Nardo","year":"1994","unstructured":"di Nardo, P., Brown, T. & Barlow, D. Anxiety Disorders Interview Schedule for DSM-IV: Lifetime version (ADIS-IV-L). (Psychological Corporation, Texas, 1994)."},{"key":"863_CR28","unstructured":"First, M., Spitzer, R., Gibbon, M. & Williams, J. Structured Clinical Interview for DSM-IV Axis I Personality Disorders (SCID-I), Clinician Version. (American Psychiatric Publishing, 2013)."},{"key":"863_CR29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.genhosppsych.2007.03.003","volume":"29","author":"JA Bourgeois","year":"2007","unstructured":"Bourgeois, J. A. et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor\/ataxia syndrome. Gen. Hosp. Psychiatry 29, 349\u2013356 (2007).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"863_CR30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.4088\/JCP.08r04476","volume":"70","author":"JA Bourgeois","year":"2009","unstructured":"Bourgeois, J. A. et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J. Clin. Psychiatry 70, 852\u2013862 (2009).","journal-title":"J. Clin. Psychiatry"},{"key":"863_CR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajmg.b.30241","volume":"139B","author":"D Hessl","year":"2005","unstructured":"Hessl, D. et al. Abnormal elevation ofFMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139B, 115\u2013121 (2005).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"863_CR32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CIA.S1794","volume":"3","author":"RJ Hagerman","year":"2008","unstructured":"Hagerman, R. J. et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin. Interv. Aging 3, 251\u2013262 (2008).","journal-title":"Clin. Interv. Aging"},{"key":"863_CR33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mds.21252","volume":"22","author":"MA Leehey","year":"2007","unstructured":"Leehey, M. A. et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov. Disord. 22, 203\u2013206 (2007).","journal-title":"Mov. Disord."},{"key":"863_CR34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/brain\/awl338","volume":"130","author":"D Hessl","year":"2007","unstructured":"Hessl, D. et al. Amygdala dysfunction in men with the fragile X premutation. Brain 130, 404\u2013416 (2007).","journal-title":"Brain"},{"key":"863_CR35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000329424","volume":"33","author":"JL Olmos-Serrano","year":"2011","unstructured":"Olmos-Serrano, J. L. & Corbin, J. G. Amygdala regulation of fear and emotionality in fragile X syndrome. Dev. Neurosci. 33, 365\u2013378 (2011).","journal-title":"Dev. Neurosci."},{"key":"863_CR36","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1523\/JNEUROSCI.1714-10.2010","volume":"30","author":"JL Olmos-Serrano","year":"2010","unstructured":"Olmos-Serrano, J. L. et al. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J. Neurosci. 30, 9929\u20139938 (2010).","journal-title":"J. Neurosci."},{"key":"863_CR37","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1523\/JNEUROSCI.2764-12.2013","volume":"33","author":"RL Vislay","year":"2013","unstructured":"Vislay, R. L. et al. Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in fragile X syndrome. J. Neurosci. 33, 7548\u20137558 (2013).","journal-title":"J. Neurosci."},{"key":"863_CR38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/GIM.0b013e3182064362","volume":"13","author":"DZ Loesch","year":"2011","unstructured":"Loesch, D. Z. et al. Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism. Genet. Med. 13, 392\u2013399 (2011).","journal-title":"Genet. Med."},{"key":"863_CR39","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/mds.23150","volume":"25","author":"D Hall","year":"2010","unstructured":"Hall, D., Pickler, L., Riley, K., Tassone, F. & Hagerman, R. Parkinsonism and cognitive decline in a fragile X mosaic male. Mov. Disord. 25, 1523\u20131524 (2010).","journal-title":"Mov. Disord."},{"key":"863_CR40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00004583-199402000-00015","volume":"33","author":"MB Dorn","year":"1994","unstructured":"Dorn, M. B., Mazzocco, M. M. & Hagerman, R. J. Behavioral and psychiatric disorders in adult male carriers of fragile X. J. Am. Acad. Child Adolesc. Psychiatry 33, 256\u2013264 (1994).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"863_CR41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bandc.2010.05.008","volume":"73","author":"CS Kogan","year":"2010","unstructured":"Kogan, C. S. & Cornish, K. M. Mapping self-reports of working memory deficits to executive dysfunction in Fragile X Mental Retardation 1 (FMR1) gene premutation carriers asymptomatic for FXTAS. Brain Cogn. 73, 236\u2013243 (2010).","journal-title":"Brain Cogn."},{"key":"863_CR42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archpsyc.65.7.826","volume":"65","author":"G Schumann","year":"2008","unstructured":"Schumann, G. et al. Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch. Gen. Psychiatry 65, 826\u2013838 (2008).","journal-title":"Arch. Gen. Psychiatry"},{"key":"863_CR43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/NDT.S45963","volume":"9","author":"GC Quintero","year":"2013","unstructured":"Quintero, G. C. Role of nucleus accumbens glutamatergic plasticity in drug addiction. Neuropsychiatr. Dis. Treat. 9, 1499\u20131512 (2013).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"863_CR44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-9158-2-10","volume":"2","author":"DI Pretto","year":"2013","unstructured":"Pretto, D. I. et al. Intranuclear inclusions in a fragile X mosaic male. Transl. Neurodegener. 2, 10 (2013).","journal-title":"Transl. Neurodegener."},{"key":"863_CR45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11689-010-9047-2","volume":"2","author":"A Utari","year":"2010","unstructured":"Utari, A. et al. Aging in fragile X syndrome. J. Neurodev. Disord. 2, 70\u201376 (2010).","journal-title":"J. Neurodev. Disord."},{"key":"863_CR46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.psychres.2012.12.022","volume":"210","author":"T Kov\u00e1cs","year":"2013","unstructured":"Kov\u00e1cs, T., Kelemen, O. & K\u00e9ri, S. Decreased fragile X mental retardation protein (FMRP) is associated with lower IQ and earlier illness onset in patients with schizophrenia. Psychiatry Res. 210, 690\u2013693 (2013).","journal-title":"Psychiatry Res."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00863-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00863-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00863-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:03:15Z","timestamp":1670248995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00863-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1038\/s41398-020-00863-w","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"19 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H. has received funding from Zynerba, Ovid, and the Azrieli Foundation for carrying out treatment studies in patients with fragile X syndrome (FXS). She has also consulted with Fulcrum, Ovid, and Zynerba regarding treatment studies in individuals with FXS. F.T. has received funds from Asuragen and Zynerba for studies in FXS and associated disorders.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"205"}}